TherapeuticsMD, Inc.
TXMD
$2.02
-$0.18-8.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.90% | -17.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.90% | -17.65% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 13.90% | -17.65% | |||
| SG&A Expenses | 79.37% | -16.26% | |||
| Depreciation & Amortization | 1.04% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 72.41% | -15.03% | |||
| Operating Income | -227.36% | 7.21% | |||
| Income Before Tax | -1,260.00% | -90.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,324.00% | -90.83% | |||
| Earnings from Discontinued Operations | -106.86% | 1,600.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -507.24% | -72.41% | |||
| EBIT | -227.36% | 7.21% | |||
| EBITDA | -336.00% | 10.31% | |||
| EPS Basic | -508.40% | -72.48% | |||
| Normalized Basic EPS | -743.18% | -85.03% | |||
| EPS Diluted | -670.00% | -78.99% | |||
| Normalized Diluted EPS | -743.18% | -85.03% | |||
| Average Basic Shares Outstanding | 0.01% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||